BCG Aşısı

Yıl 2005, Cilt: 3 Sayı: 1, 37 - 39, 01.06.2005

İşık Yalçın Nevin Hatipoğlu

Öz

BCG aşısı Paris’de Institut Pasteur’da Calmette ve Guerin tarafından M. bovis suflunun sığır safra mediumunda, 1908’de başlayıp 231 kez pasajlanması ile atenüe hale getirilmesi sonucu geliştirilmiştir. Laboratuar hayvanlarına injekte edildiğinde virulan M. tuberculosis ile karşılaşma halinde direncin arttığı gösterilmifltir. 1921 yılında ilk kez bir yenidoğana uygulanmış ve o zamandan beri 4 milyardan fazla kişiye BCG aşısı yapılmıştır 1 .

Kaynakça

• Starke JR, Smith KC. Tuberculosis. In: Feigin RD, Cherry MD, Demm- ler GJ and Kaplan SL (eds).Textbook of Pediatric Infectious Diseases (vol 1). 5th edition. Philadelphia: Saunders; 2004. p.1337-79.
• Lindgren I. pathology of tuberculous infection in BCG-vaccinated hu- mans. Adv Tuberc Res 1965; 14:203-31.
• Grange JM, Gibson J, Osborn TW, et al. What is BCG? Tubercle 1983,64:129-39.
• tenDam HG. Research on BCG vaccination. Adv Tuberc Res 1984; 21:79-106.
• Turnbull FM, McIntyre PB, Achat HM, et al. National study of adver- se reactions after vaccination with bacilli Calmette Guérin. Clin In- fect Dis 2002;34:447-53.
• Carlgren LE, Hansson CG, Henricsson L, et al. Fatal BCG infection in an infant with congenital lymphocytopenic agammaglobulinemia. Acta Paediatr Scand 1966;55:636-44.
• Esterly JR, Sturner WQ, Esterly NB, et al. Disseminated BCG in twin boys with presumed chronic. Pediatrics 1977;48:141-4.
• Gonzalez B, Moreno S, Burdach R, et al. Clinical presentation bacil- lus Calmette-Guérin infections in patients with immunodeficiency syndromes. Pediatr Infect Dis J 1989;8:201-6.
• Pederson FK, Schiotz PO, Valerius NH, et al. Fatal BCG infection in an immunocompetent girl. Acta Paediatr Scand 1978;67:19-23.
• Peltola H, Salmi I, Vahvanen V, et al. BCG vaccination as a cause of osteomyelitis and subcutaneous abscess. Arch Dis Child 1984;59:157-61.
• Braun MM, Byers RH, Heyward WL, et al. Acquired immunodefici- ency syndrome and extrapulmonary tuberculosis in the United Sta- tes. Arch Intern Med 1990;150:1913-6.
• Ryder RW, Oxtoby MJ, Mvula M, et al. Safety and immunogenicity of bacillus Calmette-Guérin, diphteria-tetanus-pertusis, and oral polio vaccines in newborn children in Zaire infected with human immuno- deficiency virus type 1. J Pediatr 1993;122:697-702.
• Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Guérin in- fection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993,12:993-7.
• Houde C and Dery P. Mycobacterium bovis sepsis in an infant with human immunodeficiency virus infection. Pediatr Infect Dis J 1988; 7:810.
• O’Brien K, Ruff A, Louis M, et al. Bacillus Calmette-Guérin complica- tions in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995;95:414-8.
• Reichman LB. Why hasn’t BCG proved dangerous in HIV-infected pa- tients? JAMA 1989;261:3246.
• Reynes J, Perez C, Lamaury I, et al. Bacille Calmette-Guérin adenitis 30 years after immunization in a patient with AIDS. J Infect Dis 1989;160:727.
• Eickhoff TC. the current status of BCG immunization against tubercu- losis. Annu Rev Med 1977;28:411-23.
• Report of a WHO Study Group: BCG vaccination policies. WHO Tech- nical report Series No. 652, 980-11.
• Curtis HM, Bamford FN and Leck I. Incidence of childhood tuberculo- sis after neonatal BCG vaccination. Lancet 1984;1:145-8.
• Colditz G, Brewer T, Berkey C, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. JAMA 1994;27:698-702.
• Colditz G, Berkey CS, Mosteller F, et al. The efficacy of bacillus Cal- mette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: Meta-analysis of the published literature. Pediatrics 1995;96:25-39.
• Centers for Disease Control and Prevention: The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuber- culosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996;45(RR-4):1-18.
• Kendig EL Jr. Prognosis of infants born of tuberculous mothers. Pedi- atrics 1960;26:97-100.
• Kendig EL Jr. The place of BCG vaccine in the management of infants born of tuberculous mothers. N Engl J Med 1969;281:520-3.
• Sirinavin S, Chotpitayasunondh T, Suwanjutha S, et al Efficacy of ne- onatal bacillus Calmette-Guérin vaccination against tuberculosis. Pediatr Infect Dis J 1991;10:359-65.
• Tidjani O, Amedome A and tenDam HG. Protective effect of BG vac- cination of the newborn against childhood tuberculosis in an African community. Tubercle 1986;67:269-81.
• Özkaya fi, Aktan Z, Özkan S, Ecevit H. Tüberkülozdan korunma. In: TC Sağlık Bakanlığı Verem Savaflı Daire Baflkanlığı Türkiye’de tüberkü- lozun kontrolü için baflvuru kitabı. Ankara: Rekmay Ltd fiti; 2003. p.58- 64.
• Koçoğlu F. Tüberküloz sorununun çözümünde günümüzde uygulanan kontrol yöntemlerinin etkinliği. In: Kocabafl A (ed). Tüberküloz, kliniği ve kontrolü. Ankara: Emel Matbaası; 1991. p.439-43.
• Ildirim I, Sapan N, Cavusoglu B. Arch Dis Child. 1992 Jan;67(1):80-2. Comparison of BCG vaccination at birth and at third month of life.
• Fine PE. BCG: The challenge continues. Scand J Infect Dis 2001;33:243-5.
• von Reyn CF and Vuola JM. New vaccines for the prevention of tuber- culosis. Vaccines CID 2002;35:465-74.
• Nor NM, Musa M. Approaches towards the development of a vacci- ne against tuberculosis: recombinant BCG and DNA vaccine. Tuber- culosis 2004;84:102-9.
• Reed SG and Campos-Neto A. Vaccines for parasitic and bacterial di- seases. Current Opinion in Immunology 2003;15:456-60. 39